The Dynamic Technology Lab Private Ltd Acquires 11,022 Shares of Ironwood Pharmaceuticals Inc. (IRWD)

The Dynamic Technology Lab Private Ltd Acquires 11,022  Shares of Ironwood Pharmaceuticals Inc. (IRWD)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,022 shares of the company’s stock, valued at approximately $144,000.

A number of other large investors have also bought and sold shares of the stock. BlackRock Group LTD raised its stake in Ironwood Pharmaceuticals by 34.8% in the first quarter. BlackRock Group LTD now owns 125,601 shares of the company’s stock valued at $1,374,000 after buying an additional 32,394 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Ironwood Pharmaceuticals by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,229,012 shares of the company’s stock valued at $35,325,000 after buying an additional 9,050 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Ironwood Pharmaceuticals by 1.3% in the first quarter. JPMorgan Chase & Co. now owns 764,631 shares of the company’s stock valued at $8,365,000 after buying an additional 10,102 shares during the last quarter. Spark Investment Management LLC raised its stake in Ironwood Pharmaceuticals by 78.7% in the first quarter. Spark Investment Management LLC now owns 197,800 shares of the company’s stock valued at $2,163,000 after buying an additional 87,100 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Ironwood Pharmaceuticals by 1.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 125,484 shares of the company’s stock valued at $1,373,000 after buying an additional 2,357 shares during the last quarter. 93.96% of the stock is currently owned by institutional investors.

Shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) opened at 15.71 on Friday. The firm has a 50-day moving average of $14.63 and a 200-day moving average of $12.80. Ironwood Pharmaceuticals Inc. has a 12-month low of $7.35 and a 12-month high of $16.17. The firm’s market cap is $2.28 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.01. The business earned $54.40 million during the quarter, compared to analyst estimates of $54.49 million. Ironwood Pharmaceuticals had a negative net margin of 45.21% and a negative return on equity of 94.75%. The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.34) earnings per share. On average, equities analysts forecast that Ironwood Pharmaceuticals Inc. will post ($0.75) earnings per share for the current fiscal year.

Several equities research analysts have recently issued reports on IRWD shares. Wedbush reissued a “neutral” rating and set a $10.00 target price on shares of Ironwood Pharmaceuticals in a research note on Friday, June 24th. Mizuho increased their target price on shares of Ironwood Pharmaceuticals from $16.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, July 15th. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, July 25th. Barclays PLC increased their target price on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, August 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of Ironwood Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals has an average rating of “Hold” and an average target price of $15.64.

In other Ironwood Pharmaceuticals news, Director Lawrence S. Olanoff sold 3,200 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $13.72, for a total value of $43,904.00. Following the transaction, the director now directly owns 29,305 shares in the company, valued at $402,064.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 7.17% of the stock is currently owned by company insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

Related posts

Leave a Comment